Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204247785> ?p ?o ?g. }
- W3204247785 endingPage "1345" @default.
- W3204247785 startingPage "1345" @default.
- W3204247785 abstract "Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer in the world. Recently, the effectiveness of new antiviral therapies and the HBV vaccine have reduced HCC's incidence, while non-alcoholic steato-hepatitis is an emerging risk factor. This review focuses on antiangiogenic molecules and immune checkpoint inhibitors approved for HCC treatment and possible future approaches. Sorafenib was the first drug approved for the treatment of advanced HCC (aHCC) and it has been shown to increase survival by a few months. Lenvatinib, a multikinase inhibitor, has shown non-inferiority in survival compared with sorafenib and an improvement in progression-free survival (PFS). The combination of atezolizumab (an anti-PDL1 antibody) and bevacizumab (an anti-VEGF antibody) was the first drug combination approved for HCC, demonstrating improved survival compared with sorafenib (19.2 vs. 13.4 months). As a second line of therapy, three regimens (regorafenib, cabozantinib, and ramucirumab) have been approved for the treatment of aHCC after progression on sorafenib according to guidelines. Furthermore, nivolumab, pembrolizumab, and nivolumab plus ipilimumab have been approved by the FDA (2017, 2018, and 2020, respectively). Finally, immune target therapy, cancer vaccines, and epigenetic drugs represent three new possible weapons for the treatment of HCC." @default.
- W3204247785 created "2021-10-11" @default.
- W3204247785 creator A5007407416 @default.
- W3204247785 creator A5031221374 @default.
- W3204247785 creator A5044045902 @default.
- W3204247785 creator A5044721317 @default.
- W3204247785 creator A5046840156 @default.
- W3204247785 creator A5053911144 @default.
- W3204247785 creator A5055583365 @default.
- W3204247785 date "2021-09-28" @default.
- W3204247785 modified "2023-10-06" @default.
- W3204247785 title "HCC and Molecular Targeting Therapies: Back to the Future" @default.
- W3204247785 cites W1825553076 @default.
- W3204247785 cites W1828082159 @default.
- W3204247785 cites W1920868372 @default.
- W3204247785 cites W1971837077 @default.
- W3204247785 cites W1976734399 @default.
- W3204247785 cites W1991327582 @default.
- W3204247785 cites W1994193851 @default.
- W3204247785 cites W1997533142 @default.
- W3204247785 cites W2029029081 @default.
- W3204247785 cites W2042450295 @default.
- W3204247785 cites W2080588989 @default.
- W3204247785 cites W2116922255 @default.
- W3204247785 cites W2127618040 @default.
- W3204247785 cites W2132286877 @default.
- W3204247785 cites W2150862707 @default.
- W3204247785 cites W2277004004 @default.
- W3204247785 cites W2286222994 @default.
- W3204247785 cites W2368891327 @default.
- W3204247785 cites W2395095892 @default.
- W3204247785 cites W2413809012 @default.
- W3204247785 cites W2463909130 @default.
- W3204247785 cites W2497822529 @default.
- W3204247785 cites W2521441342 @default.
- W3204247785 cites W2535442639 @default.
- W3204247785 cites W2560284650 @default.
- W3204247785 cites W2560499218 @default.
- W3204247785 cites W2570611720 @default.
- W3204247785 cites W2582578898 @default.
- W3204247785 cites W2591251277 @default.
- W3204247785 cites W2591965511 @default.
- W3204247785 cites W2603690292 @default.
- W3204247785 cites W2606367731 @default.
- W3204247785 cites W2611153764 @default.
- W3204247785 cites W2621228126 @default.
- W3204247785 cites W2625559053 @default.
- W3204247785 cites W2626033245 @default.
- W3204247785 cites W2727497670 @default.
- W3204247785 cites W2787358630 @default.
- W3204247785 cites W2790857274 @default.
- W3204247785 cites W2794930605 @default.
- W3204247785 cites W2795708663 @default.
- W3204247785 cites W2799933121 @default.
- W3204247785 cites W2803110658 @default.
- W3204247785 cites W2803637437 @default.
- W3204247785 cites W2804478743 @default.
- W3204247785 cites W2805592007 @default.
- W3204247785 cites W2883286004 @default.
- W3204247785 cites W2884770968 @default.
- W3204247785 cites W2885329437 @default.
- W3204247785 cites W2889932786 @default.
- W3204247785 cites W2893630718 @default.
- W3204247785 cites W2895479306 @default.
- W3204247785 cites W2896922600 @default.
- W3204247785 cites W2897252521 @default.
- W3204247785 cites W2901259053 @default.
- W3204247785 cites W2902005676 @default.
- W3204247785 cites W2902109874 @default.
- W3204247785 cites W2905526808 @default.
- W3204247785 cites W2908573150 @default.
- W3204247785 cites W2912201468 @default.
- W3204247785 cites W2914676498 @default.
- W3204247785 cites W2916468143 @default.
- W3204247785 cites W2917680953 @default.
- W3204247785 cites W2933419869 @default.
- W3204247785 cites W2938499540 @default.
- W3204247785 cites W2945730831 @default.
- W3204247785 cites W2947412116 @default.
- W3204247785 cites W2948172856 @default.
- W3204247785 cites W2948320538 @default.
- W3204247785 cites W2949512677 @default.
- W3204247785 cites W2952311394 @default.
- W3204247785 cites W2952676090 @default.
- W3204247785 cites W2953824893 @default.
- W3204247785 cites W2954476990 @default.
- W3204247785 cites W2957370227 @default.
- W3204247785 cites W2958131887 @default.
- W3204247785 cites W2963391693 @default.
- W3204247785 cites W2969846817 @default.
- W3204247785 cites W2970832772 @default.
- W3204247785 cites W2980928406 @default.
- W3204247785 cites W2982376008 @default.
- W3204247785 cites W2982497080 @default.
- W3204247785 cites W2982510680 @default.
- W3204247785 cites W2985015507 @default.
- W3204247785 cites W2990602950 @default.
- W3204247785 cites W2991181995 @default.